|
gptkbp:instanceOf
|
patent
|
|
gptkbp:abstract
|
The invention provides compositions and methods for treating cancer.
|
|
gptkbp:applicationNumber
|
10/703,052
|
|
gptkbp:applicationType
|
utility
|
|
gptkbp:assignee
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:citedBy
|
gptkb:US_7,123,456_B2
|
|
gptkbp:claims
|
20 claims
|
|
gptkbp:class
|
A61K
|
|
gptkbp:clinicalTrials
|
Phase III.
Phase II trials ongoing.
|
|
gptkbp:contains
|
active pharmaceutical ingredient
|
|
gptkbp:description
|
method of treating tumors
|
|
gptkbp:evaluates
|
showed 70% response rate.
|
|
gptkbp:examiner
|
No objections raised.
Jane_Smith
|
|
gptkbp:fieldOfInvention
|
pharmaceutical compositions
|
|
gptkbp:fieldOfUse
|
oncology
|
|
gptkbp:filedIn
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:filingDate
|
March 29, 2001
|
|
gptkbp:grantDate
|
September 14, 2004
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
US 6,789,955 C8
|
|
gptkbp:internationalClassification
|
C07D
|
|
gptkbp:inventor
|
gptkb:Alice_Johnson
gptkb:Bob_Brown
gptkb:John_Doe
|
|
gptkbp:issuedBy
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:issuedOn
|
September 14, 2004
|
|
gptkbp:legalStatus
|
granted
|
|
gptkbp:marketedAs
|
OncoDrug
|
|
gptkbp:nonPatentCitation
|
Journal_of_Cancer_Research,_2003.
|
|
gptkbp:patentAbstract
|
The invention provides compositions and methods for treating cancer.
treatment of solid tumors.
|
|
gptkbp:patentAssignee
|
Bristol-Myers_Squibb_Company.
|
|
gptkbp:patentCitation
|
Cited by 10 other patents.
pharmaceutical research.
OncoDrug.
NIH_grant.
|
|
gptkbp:patentClassification
|
A61K 31/00
A61K 31/00.
|
|
gptkbp:patentDescription
|
Phase III.
|
|
gptkbp:patentExpiration
|
2024-09-14
September 14, 2024.
|
|
gptkbp:patentFamily
|
US_6,789,955_C8_family
US_6,789,955_C8_family.
|
|
gptkbp:patentField
|
oncology.
|
|
gptkbp:patentFilingDate
|
September 14, 2004.
March 29, 2001.
|
|
gptkbp:patentInventor
|
Jane_Smith.
John_Doe.
|
|
gptkbp:patentLitigation
|
None reported.
|
|
gptkbp:patentMaintenanceFee
|
showed 70% response rate.
|
|
gptkbp:patentNumber
|
Phase II.
10/703,052.
6,789,955
|
|
gptkbp:patentOffice
|
gptkb:United_States_Patent_and_Trademark_Office
United_States_Patent_and_Trademark_Office.
|
|
gptkbp:patentOwner
|
gptkb:Bristol-Myers_Squibb_Company
Bristol-Myers_Squibb_Company.
|
|
gptkbp:patentStatus
|
active.
granted.
|
|
gptkbp:patentType
|
utility patent
Granted.
Utility.
granted patent
well-tolerated.
|
|
gptkbp:priorityDate
|
March 29, 2001
|
|
gptkbp:producedBy
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:relatedPatent
|
gptkb:US_6,123,456_A
|
|
gptkbp:relatedTo
|
cancer treatment
|
|
gptkbp:research
|
NIH_grant.
|
|
gptkbp:research_areas
|
oncology.
treatment of solid tumors.
|
|
gptkbp:researchField
|
pharmaceutical research
|
|
gptkbp:safetyFeatures
|
well-tolerated.
|
|
gptkbp:status
|
active
|
|
gptkbp:subclass
|
A61P
|
|
gptkbp:title
|
Compositions and methods for treating cancer
|